Paras Healthcare Ltd

Paras Healthcare Ltd has announced that its Board of Directors has authorized key managerial personnel (KMPs) to determine the materiality of events or information and to make disclosures to stock exchanges. This authorization is in compliance with Regulation 30(5) of the SEBI Listing Regulations. The authorized KMPs include Dr. Dharminder Kumar Nagar (Managing Director), Dr. Kapil Garg (Whole Time Director), Mr. Dilip Bidani (Group Chief Financial Officer), and Mr. Rahul Kumar (Company Secretary and Compliance Officer). The details of this authorization will be available on the company's website.

Paras Healthcare Ltd has announced the closure of its trading window for dealing in the company's securities. This closure will be effective from Wednesday, October 28, 2026, and will remain in effect until 48 hours after the declaration of the Unaudited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2026. All designated persons and their immediate relatives are prohibited from trading in the company's securities during this period. The date of the board meeting to approve these financial results will be intimated separately. The disclosure will also be available on the company's investor website.

Paras Healthcare Ltd has announced the appointment of Mr. Rahul Kumar as the new Compliance Officer, effective July 22, 2024. Mr. Kumar, who is also the Company Secretary and a Key Managerial Personnel (KMP), will oversee compliance matters for the company. This appointment is in accordance with Regulation 6(1) of the SEBI Listing Regulations. The company will host this disclosure on its investor relations website.

Paras Healthcare Ltd has appointed MUFG Intime India Private Limited (formerly Link Intime India Private Limited) as its Registrar to an Issue & Share Transfer Agent (RTA). This appointment is in compliance with Regulation 7(1) of the SEBI Listing Regulations. The company will also host this disclosure on its investor relations website.

Paras Healthcare Ltd has adopted and approved a "Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information" (UPSI) as per Regulation 8(2) of the SEBI PIT Regulations. The code, approved by the Board of Directors on October 26, 2026, aims to ensure timely and adequate disclosure of UPSI to maintain uniformity, transparency, and fairness. It has been made available on the company's website and will be hosted there. The code defines key terms like UPSI and Legitimate Purpose and outlines principles for prompt disclosure, refraining from discriminatory disclosure, appointing a Chief Investor Relations Officer, and managing UPSI on a need-to-know basis.